COVID-19: In Vitro Diagnostic Testing
January 11, 2021Effective 1/1/2021 Policy 0557
Coverage Policy addresses in vitro diagnostic testing methods to detect the presence of, or suspected exposure to the SARS-CoV-2 virus which causes COVID-19 infection. Molecular tests and antigen tests are considered diagnostic of an active infection with the SARS-CoV-2 virus. In general, antibody (serology) tests are not diagnostic; rather, they are used to identify individuals who have developed antibodies against the SARSCoV-2 virus and may be used for public health purposes such as population prevalence estimates. The Coverage Policy applies to both individual and pooled testing methods.
The source page for this article has moved or has expired.
Please visit the Billing Beat News or Beyond Billing Blog for relevant information or search our site for specific information related to this article.
Original source URL:
https://static.cigna.com/assets/chcp/pdf/coveragePolicies/medical/mm_0557_coveragepositioncriteria_covid-19_in_vitro_diagnostic_testing.pdf